Jump to content

Atevirdine

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Nemo bis (talk | contribs) at 05:45, 2 August 2019 (Alter: pages. Removed URL that duplicated unique identifier. Formatted dashes. | You can use this tool yourself. Report bugs here.). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Atevirdine
Names
IUPAC name
[4-[3-(Ethylamino)pyridin-2-yl]piperazin-1-yl]-(5-methoxy-1H-indol-2-yl)methanone
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
UNII
  • InChI=1S/C21H25N5O2/c1-3-22-18-5-4-8-23-20(18)25-9-11-26(12-10-25)21(27)19-14-15-13-16(28-2)6-7-17(15)24-19/h4-8,13-14,22,24H,3,9-12H2,1-2H3 checkY
    Key: UCPOMLWZWRTIAA-UHFFFAOYSA-N checkY
  • InChI=1/C21H25N5O2/c1-3-22-18-5-4-8-23-20(18)25-9-11-26(12-10-25)21(27)19-14-15-13-16(28-2)6-7-17(15)24-19/h4-8,13-14,22,24H,3,9-12H2,1-2H3
    Key: UCPOMLWZWRTIAA-UHFFFAOYAK
  • O=C(N2CCN(c1ncccc1NCC)CC2)c4cc3cc(OC)ccc3[nH]4
Properties
C21H25N5O2
Molar mass 379.46 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)

Ateviridine is a non-nucleoside reverse transcriptase inhibitor that has been studied for the treatment of HIV.[1]

Synthesis

Atevirdine synthesis:[2][3] SAR:[4]

Preparation of the pyridylpiperazine moiety starts by aromatic displacement of chlorine from 2-chloro-3-nitropyridine by piperazine to give 3. The secondary amine is then protected as its BOC derivative by reaction with di-tert-butyl dicarbonate (Boc anhydride) to give 4. The nitro group is then reduced by catalytic hydrogenation. Reductive alkylation with acetaldehyde in the presence of lithium cyanoborohydride gives the corresponding N-ethyl derivative. The protecting group is then removed by reaction with TFA. Reaction of the resulting amine with the imidazolide derivative of 5-methoxy-3-indoleacetic acid produces the amide reverse transcriptase inhibitor, atevirdine.

See also

References

  1. ^ Morse GD, Reichman RC, Fischl MA, et al. (January 2000). "Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teams". Antiviral Res. 45 (1): 47–58. doi:10.1016/S0166-3542(99)00073-X. PMID 10774589.
  2. ^ D. L. Romero, Drugs Future 19, 9 (1995).
  3. ^ D. L. Romero et al., WO 9109849  (1991 to Upjohn).
  4. ^ Romero, D. L.; Morge, R. A.; Biles, C.; Berrios-Pena, N.; May, P. D.; Palmer, J. R.; Johnson, P. D.; Smith, H. W.; Busso, M.; et al. (1994). "Discovery, Synthesis, and Bioactivity of Bis(heteroaryl)piperazines. 1. A Novel Class of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors". Journal of Medicinal Chemistry. 37 (7): 999–1014. doi:10.1021/jm00033a018. PMID 7512142.


Stub icon

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Atevirdine&oldid=908968326"